![Vivian Berlin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Vivian Berlin is a Director-Business Development at Office of Technology Development.
Prior to joining OTD in 2008, she spent the previous 17 years at Vertex Pharmaceuticals, Mitotix and GPC Biotech.
Dr. Berlin has led multiple R&D programs, advanced programs from discovery to late pre-clinical development, and helped to establish proprietary positions in several therapeutic areas.
She has also been a strategic consultant to several life science companies and investor groups.
Dr. Berlin holds an MS from the Harvard School of Public Health, a PhD from Stanford University and was a postdoctoral fellow at the Whitehead Institute for Biomedical Research.
| Companies | Position | End |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions. | Private Equity Investor | 06/10/2010 |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions. | Finance |
Select your edition
All financial news and data tailored to specific country editions
Choose MarketScreener 
